Medicare Enrolled

Dr. Ragisha Gopalakrishnan, M.D.

Medical Oncology · Burlington, MA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Consulting-driven
41 MALL RD, Burlington, MA 01805
7817448000
In practice since 2013 (13 years)
NPI: 1538502620 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gopalakrishnan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gopalakrishnan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gopalakrishnan

Dr. Ragisha Gopalakrishnan is a medical oncology specialist in Burlington, MA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Gopalakrishnan performed 306 Medicare services across 154 unique beneficiaries.

Between the years covered by Open Payments, Dr. Gopalakrishnan received a total of $15,563 from 55 pharmaceutical and/or device companies across 319 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gopalakrishnan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 13 years in practice ▲ Top 40% volume in MA $15,563 industry payments

Medicare Practice Summary

Medicare Utilization ↗
306
Medicare services
Top 40% in MA for medical oncology
154
Unique beneficiaries
$93
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~24 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
197 $81 $252
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
35 $98 $329
New patient office visit, complex (60-74 min) 26 $153 $552
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
21 $124 $356
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
15 $112 $449
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
12 $57 $165
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$15,563
Total received (2019-2024)
Avg $3,113/year across 5 years
Top 35% in MA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
319
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,551 (61.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,849 (37.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$163 (1.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,490
2023
$9,077
2022
$4,548
2021
$435
2019
$13

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$249
Daiichi Sankyo Inc.
$213
Tempus AI, Inc
$156
PFIZER INC.
$110
Novartis Pharmaceuticals Corporation
$83
AstraZeneca Pharmaceuticals LP
$77
Mirati Therapeutics, Inc.
$68
Janssen Biotech, Inc.
$65
Incyte Corporation
$44
SpringWorks Therapeutics, Inc.
$43
Alexion Pharmaceuticals, Inc.
$35
GENZYME CORPORATION
$33
Genmab U.S., Inc.
$24
Deciphera Pharmaceuticals Inc.
$23
Gilead Sciences, Inc.
$23
EMD Serono, Inc.
$23
ARRAY BIOPHARMA INC
$22
Merck Sharp & Dohme LLC
$22
Karyopharm Therapeutics Inc.
$21
Takeda Pharmaceuticals U.S.A., Inc.
$21
Astellas Pharma US Inc
$20
ABBVIE INC.
$19
Genentech USA, Inc.
$19
E.R. Squibb & Sons, L.L.C.
$19
Pharmacosmos Therapeutics Inc.
$18
BeiGene USA, Inc.
$14
Lilly USA, LLC
$13
Stemline Therapeutics Inc.
$13
Top 3 companies account for 41.5% of 2024 payments
All-time payments by company (2019-2024) ›
EISAI INC.
$2,857
AstraZeneca Pharmaceuticals LP
$2,747
Gilead Sciences, Inc.
$2,707
PFIZER INC.
$1,426
Celgene Corporation
$814
Daiichi Sankyo Inc.
$564
Novartis Pharmaceuticals Corporation
$526
Janssen Biotech, Inc.
$479
Genmab U.S., Inc.
$290
Seagen Inc.
$234
Merck Sharp & Dohme LLC
$220
GENZYME CORPORATION
$216
Sirtex Medical Inc
$165
Tempus AI, Inc
$156
Incyte Corporation
$141
Mirati Therapeutics, Inc.
$134
GlaxoSmithKline, LLC.
$133
ABBVIE INC.
$128
EMD Serono, Inc.
$127
Genentech USA, Inc.
$120
SERVIER PHARMACEUTICALS LLC
$109
ARRAY BIOPHARMA INC
$98
MorphoSys, US Inc.
$85
Astellas Pharma US Inc
$79
Puma Biotechnology, Inc.
$74
Stemline Therapeutics Inc.
$72
Adaptive Biotechnologies Corporation
$63
Amgen Inc.
$61
Deciphera Pharmaceuticals Inc.
$45
Exelixis Inc.
$44
SpringWorks Therapeutics, Inc.
$43
Merck Sharp & Dohme Corporation
$42
Pharmacyclics LLC, An AbbVie Company
$40
Takeda Pharmaceuticals U.S.A., Inc.
$36
Alexion Pharmaceuticals, Inc.
$35
ADC Therapeutics America, Inc.
$34
AVEO Pharmaceuticals, Inc.
$32
Blueprint Medicines Corporation
$32
Dendreon Pharmaceuticals LLC
$31
Myriad Genetic Laboratories, Inc.
$28
BeiGene USA, Inc.
$27
JAZZ PHARMACEUTICALS INC.
$25
Myovant Sciences Inc.
$24
Epizyme, Inc.,
$24
Karyopharm Therapeutics Inc.
$21
TAIHO ONCOLOGY, INC.
$20
Eisai Inc.
$20
Kite Pharma, Inc.
$20
G1 Therapeutics, Inc.
$20
AbbVie Inc.
$20
E.R. Squibb & Sons, L.L.C.
$19
Pharmacosmos Therapeutics Inc.
$18
Lilly USA, LLC
$13
Tosoh Bioscience, Inc.
$13
Janssen Pharmaceuticals, Inc
$12
Top 3 companies account for 53.4% of all-time payments
Associated products mentioned in payments ›
27.29 · ADCETRIS · AIA-PACK Sample Diluting Solution · AYVAKIT · Alecensa · BAVENCIO · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · COSELA · Cabometyx · DARZALEX · ELITEK · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Enhertu · Epkinly · FOTIVDA · FRUZAQLA · Fabhalta · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LONSURF · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MONJUVI · Nplate · OGSIVEO · ONUREG · OPDIVO · ORGOVYX · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROVENGE · Padcev · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · TABRECTA · TAGRISSO · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · XARELTO · XPOVIO · XT CDX · Xospata · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (61%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Looking for a medical oncology specialist in Burlington?
Compare medical oncologists in the Burlington area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Gopalakrishnan is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Gopalakrishnan experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Gopalakrishnan performed 197 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gopalakrishnan receive payments from pharmaceutical companies?
Yes. Dr. Gopalakrishnan received a total of $15,563 from 55 companies across 319 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gopalakrishnan's costs compare to other medical oncologists in Burlington?
Dr. Gopalakrishnan's average Medicare payment per service is $93. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gopalakrishnan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →